Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06720896 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.

Study acronym: VISTA-1
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 19, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v6
  2. Primary and study completion dates: Apr 2026 to Jun 2026v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Feb 2026 to Apr 2026
    • Start date changed from estimate of Sep 2025 to Nov 1, 2025
    • Site details revised at 2 of 2 sites
    v4
  4. Start date: May 2025 to Sep 2025
    • Study sites: 1 to 2
    • Primary and study completion dates: Dec 2025 to Feb 2026
    v3
  5. Start date: Jan 2025 to May 2025v2 Show 4 more changesShow less
    • Primary completion date: Jun 2025 to Dec 2025
    • Study completion date: Jul 2025 to Dec 2025
    • Site contact updated
    • Study title expanded, about 13 words
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to its vehicle control, and to establish that the therapeutic is safe and generally well tolerated by patients.
Trial Details
NCT Number NCT06720896
Lead Sponsor Aperta Biosciences, LLC
Conditions
(from sponsor)		 Blepharitis
Related terms Blepharitis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov